732 related articles for article (PubMed ID: 31173696)
21. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
22. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
23. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
24. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
[TBL] [Abstract][Full Text] [Related]
25. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.
Yin J; Luo Y; Deng H; Qin S; Tang W; Zeng L; Zhou B
J Ethnopharmacol; 2014 May; 154(1):229-39. PubMed ID: 24735863
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis.
BinMowyna MN; AlFaris NA; Al-Sanea EA; AlTamimi JZ; Aldayel TS
Arch Physiol Biochem; 2024 Jun; 130(3):300-315. PubMed ID: 35254877
[TBL] [Abstract][Full Text] [Related]
27. Arctigenin protects against steatosis in WRL68 hepatocytes through activation of phosphoinositide 3-kinase/protein kinase B and AMP-activated protein kinase pathways.
Chen KY; Lin JA; Yao HY; Hsu AC; Tai YT; Chen JT; Hsieh MC; Shen TL; Hsu RY; Wu HT; Wang GH; Ho BY; Chen YP
Nutr Res; 2018 Apr; 52():87-97. PubMed ID: 29525610
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.
Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C
PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777
[TBL] [Abstract][Full Text] [Related]
29. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
Kang OH; Kim SB; Mun SH; Seo YS; Hwang HC; Lee YM; Lee HS; Kang DG; Kwon DY
Int J Mol Med; 2015 Mar; 35(3):803-9. PubMed ID: 25605057
[TBL] [Abstract][Full Text] [Related]
30. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
Li X; Wang Z; Klaunig JE
Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
[TBL] [Abstract][Full Text] [Related]
31. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling.
Li SW; Takahara T; Que W; Fujino M; Guo WZ; Hirano SI; Ye LP; Li XK
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G450-G463. PubMed ID: 33439102
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
[TBL] [Abstract][Full Text] [Related]
33. CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD
Xie L; Wen K; Li Q; Huang CC; Zhao JL; Zhao QH; Xiao YF; Guan XH; Qian YS; Gan L; Wang LF; Deng KY; Xin HB
Int J Biol Sci; 2021; 17(15):4305-4315. PubMed ID: 34803499
[TBL] [Abstract][Full Text] [Related]
34. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
Jiang Y; Chen L; Wang H; Narisi B; Chen B
J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
[TBL] [Abstract][Full Text] [Related]
35. A novel combination of metformin and resveratrol alleviates hepatic steatosis by activating autophagy through the cAMP/AMPK/SIRT1 signaling pathway.
Afshari H; Noori S; Zarghi A
Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3135-3148. PubMed ID: 37209153
[TBL] [Abstract][Full Text] [Related]
36. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.
Chen S; Sun S; Feng Y; Li X; Yin G; Liang P; Yu W; Meng D; Zhang X; Liu H; Zhang F
Eur J Pharmacol; 2023 Aug; 952():175808. PubMed ID: 37263401
[TBL] [Abstract][Full Text] [Related]
37. Improvement of the hepatic lipid status in intrauterine growth retarded pigs by resveratrol is related to the inhibition of mitochondrial dysfunction, oxidative stress and inflammation.
Cheng K; Jia P; Ji S; Song Z; Zhang H; Zhang L; Wang T
Food Funct; 2021 Jan; 12(1):278-290. PubMed ID: 33300526
[TBL] [Abstract][Full Text] [Related]
38. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
[TBL] [Abstract][Full Text] [Related]
39. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.
Ahmad A; Ali T; Kim MW; Khan A; Jo MH; Rehman SU; Khan MS; Abid NB; Khan M; Ullah R; Jo MG; Kim MO
Metabolism; 2019 Jan; 90():31-43. PubMed ID: 30473057
[TBL] [Abstract][Full Text] [Related]
40. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Wang P; Wang J; Li D; Ke W; Chen F; Hu X
J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
